Key result
Antipsychotic treatment in patients with schizophrenia is associated with increased cardiovascular risk factors, including weight gain, dyslipidemia, and diabetes mellitus.
Why the study?
What is the relationship between antipsychotic treatment and cardiovascular disease risk in patients with schizophrenia?
What is the relationship between antipsychotic treatment and cardiovascular disease risk in patients with schizophrenia?
Antipsychotic medications, particularly clozapine and olanzapine, exacerbate cardiovascular risk factors in patients with schizophrenia, highlighting the need for better cardiovascular disease management in this population.
Answers are grounded in this paper and cite their sources.
May warrant CV risk monitoring with antipsychotics in schizophrenia; confirms excess mortality but leaves optimal mitigation strategies open.
PURPOSE OF REVIEW: Schizophrenia is associated with increased mortality and reduced life expectancy, with cardiovascular disease being the most frequent cause of death. Antipsychotics have detrimental effects on different risk factors for cardiovascular disease. This review will focus on the relationship between antipsychotic treatment and cardiovascular disease. RECENT FINDINGS: The increased overall mortality and mortality from cardiovascular disease in schizophrenia are now well documented. Patients with schizophrenia are at risk of receiving less optimal treatment for cardiovascular disease. Patients with schizophrenia are at high risk of metabolic syndrome, a cluster of risk factors for cardiovascular disease. Some antipsychotics, in particular, clozapine and olanzapine, frequently cause weight gain, dyslipidemia and diabetes mellitus. Antipsychotics differ in their effects on body weight, lipids and glucose regulation. However, the long-term effects of these differences between individual antipsychotics on overall mortality and cardiovascular mortality are not well established. SUMMARY: More research is needed to better understand the relationship between schizophrenia, antipsychotic treatment and cardiovascular disease. More effective treatment strategies need to be developed to reduce the burden of cardiovascular disease in schizophrenia.
No takes yet. Share an insight, caveat, or question.
Thomas J. Raedler (2010) conducted a review in Schizophrenia. Antipsychotics was evaluated. Antipsychotic treatment in patients with schizophrenia is associated with increased cardiovascular risk factors, including weight gain, dyslipidemia, and diabetes mellitus.
Synapse has enriched 10 related papers. Consider them for comparative context: